Hepatic fibrosis in paired biopsies from deferiprone-treated patients
| . | HCV− . | HCV+ . | Pfor HCV− versus HCV+ . | |||||
|---|---|---|---|---|---|---|---|---|
| Entry . | Final . | P . | Entry . | Final . | P . | Entry . | Final . | |
| Mean Laennec grade, all pathologists | 0.71 ± 0.65 | 0.70 ± 0.53 | .91 (n = 11) | 1.26 ± 0.73 | 1.35 ± 0.90 | .41 (n = 45) | .02 | .03 |
| Mean Ishak grade, all pathologists | 1.12 ± 1.07 | 0.97 ± 0.84 | .42 (n = 11) | 1.91 ± 1.13 | 2.04 ± 1.30 | .43 (n = 45) | .04 | .01 |
| Mean Ishak grade after removing “inadequate” biopsies | 1.06 ± 1.29 | 1.11 ± 1.09 | .74 (n = 6) | 2.08 ± 1.18 | 2.14 ± 1.29 | .75 (n = 28) | .07 | .08 |
| Mean Ishak grade after removing biopsies with fewer than 6 portal tracts | 1.47 ± 1.15 | 1.53 ± 0.80 | .75 (n = 5) | 2.17 ± 1.12 | 2.04 ± 1.19 | .51 (n = 26) | .21 | .37 |
| Percentage of patients with mean Ishak grade greater than 2 | 18.2 | 9.1 | 1.0 (n = 11) | 44.4 | 46.7 | 1.0 (n = 45) | > .05 | > .05 |
| . | HCV− . | HCV+ . | Pfor HCV− versus HCV+ . | |||||
|---|---|---|---|---|---|---|---|---|
| Entry . | Final . | P . | Entry . | Final . | P . | Entry . | Final . | |
| Mean Laennec grade, all pathologists | 0.71 ± 0.65 | 0.70 ± 0.53 | .91 (n = 11) | 1.26 ± 0.73 | 1.35 ± 0.90 | .41 (n = 45) | .02 | .03 |
| Mean Ishak grade, all pathologists | 1.12 ± 1.07 | 0.97 ± 0.84 | .42 (n = 11) | 1.91 ± 1.13 | 2.04 ± 1.30 | .43 (n = 45) | .04 | .01 |
| Mean Ishak grade after removing “inadequate” biopsies | 1.06 ± 1.29 | 1.11 ± 1.09 | .74 (n = 6) | 2.08 ± 1.18 | 2.14 ± 1.29 | .75 (n = 28) | .07 | .08 |
| Mean Ishak grade after removing biopsies with fewer than 6 portal tracts | 1.47 ± 1.15 | 1.53 ± 0.80 | .75 (n = 5) | 2.17 ± 1.12 | 2.04 ± 1.19 | .51 (n = 26) | .21 | .37 |
| Percentage of patients with mean Ishak grade greater than 2 | 18.2 | 9.1 | 1.0 (n = 11) | 44.4 | 46.7 | 1.0 (n = 45) | > .05 | > .05 |
Data are derived from the mean grade for the 3 pathologists. Thet-test was used except in the last row, where Fisher exact test was used.